Considering medication exposure in genomic association studies of cognition in psychotic disorders

Seenae Eum, Scot Kristian Hill, Jeffrey R. Bishop

Research output: Contribution to journalReview articlepeer-review

Abstract

Cognitive dysfunction is a core feature of psychosis-spectrum illnesses, and the characterization of related genetic mechanisms may provide insights regarding the disease pathophysiology. Substantial efforts have been made to determine the genetic component of cognitive symptoms, without clear success. Illness-related moderators and environmental factors such as medications hinder the detection of genomic association with cognition. Polypharmacy is common in psychotic disorders, and the cumulative effects of medication regimens can confound gene-cognition associations. A review of the relative contributions of important pharmacological and genetic relationships identifies that the effects of medications on cognition in psychotic disorders may be at least, if not more, impactful than individual genes, thus underscoring the importance of accounting for medication exposure in gene-cognition association studies.

Original languageEnglish (US)
Pages (from-to)791-806
Number of pages16
JournalPharmacogenomics
Volume23
Issue number14
DOIs
StatePublished - Sep 1 2022

Keywords

  • anticholinergics
  • antidopaminergics
  • BDNF
  • cognition
  • COMT
  • genomic associations
  • medication exposure
  • psychotic disorders

PubMed: MeSH publication types

  • Journal Article
  • Review

Fingerprint

Dive into the research topics of 'Considering medication exposure in genomic association studies of cognition in psychotic disorders'. Together they form a unique fingerprint.

Cite this